Regulation news from FierceBiotech
News
Mass. Governor to sign $1B incentives plan
Thousands of biotech execs flocking to San Diego for the annual BIO meeting are likely to hear an earful from Massachusetts Governor Deval Patrick, who will be arriving with a freshly approved, $1 Read more...
Massachusetts closer on biotech bill
Lawmakers in Massachusetts are edging ever closer to approving the state's ambitious $1 billion incentives program to help foster its thriving biotech industry. That gives Governor Deval Patrick just Read more...
Developer blueprints $1B Cambridge biotech complex
Alexandria Real Estate Equities is blueprinting a billion-dollar, 1.5 million-square-foot complex of laboratories in Cambridge, MA to cater to the region's bustling life sciences industry. The Read more...
Are Mass. lawmakers 'anti-biopharmaceutical'?
After coming up with a billion-dollar program to encourage the growth of the Read more...
Biotech's next big opportunity: Follow-ons?
Follow-on biologics are often cited as major long-term threat to the biotech industry, which so far has not had to face a future where generic therapies are allowed to slice and dice the market for Read more...
Harvard prez says NIH funding system is broken
Harvard President Drew Faust has crunched the numbers on NIH funding of extramural research programs and concludes that the government-backed system to support biotech research efforts is broken. Read more...
NJ officials want to expand biopharma biz
A state economist for New Jersey has spelled out some of the biggest threats to the Garden State's biopharma industry. In a recent address, James Hughes underscored that New Jersey is losing its Read more...
Canadian regulators forging new biosimilar pathway
While U.S. lawmakers jawbone about a regulatory pathway for biosimilars, or biogenerics, Read more...
Follow-on legislation follows a twisted path in DC
BIO is toasting proposed new legislation that would provide more than 14 years of patent protection on a biologic. Needless to say, the generics crowd is just a tad disappointed by the bill, saying Read more...
Debate over follow-ons focus on market exclusivity
The Boston Globe weighs in with a lengthy look at the tussle over biogenerics--a.k.a. follow-ons and biosimilars. The smart money is betting that at some point in the not-too-distant future Congress Read more...
Get more Regulation coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends